Federal Bill: HR 3821

Bill Summary

HR 3821, the ADINA Act (Allergen Disclosure In Non-food Articles Act), would amend the Federal Food, Drug, and Cosmetic Act to require pharmaceutical manufacturers to clearly label all drug products that contain ingredients derived from major food allergens (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, soybeans) or gluten-containing grains. The label must identify each specific allergen or grain type present in the medication. The requirement would take effect either on a date set by the Secretary of HHS or within two years of enactment, whichever is sooner. The bill aims to help consumers with food allergies or sensitivities make informed decisions about medications by providing transparent ingredient disclosure.

Why It Matters to MAHA

This bill directly advances MAHA's core principle of transparency in healthcare and supports patient autonomy by giving consumers the information they need to protect their health. Allergen disclosure on medications is a critical safety measure that empowers patients to make informed decisions about their treatment options without unnecessary regulatory burden on manufacturers. The bipartisan sponsorship demonstrates broad agreement that transparency requirements serve patient interests, not corporate interests. Clear labeling of allergen-derived ingredients respects individual health needs and allows patients to choose medications that align with their specific allergies or dietary restrictions. This is transparency-driven health freedom at its best.